REX-001市場：市場規模、予測、新たな洞察-2032年

最も活性の高い細胞を選別し、成分（赤血球や血小板など）を除去することで、細胞の治療活性を低下させる可能性のある天然組織抽出物由来の多細胞治療薬（MCT）です。Ixakaは、MCT製品REX-001をリードしています。これは、CLTIの治療に患者の骨髄から採取した細胞を使用するという確立された生物学に基づく複合多細胞製品です。この製品は、白血球を濃縮した自家骨髄由来細胞懸濁液です。前駆細胞と免疫細胞（リンパ球、単球、顆粒球）の組み合わせからなります。

CLTIの臨床的進行につながる複雑な疾患プロセス（プラークの沈着、炎症、虚血、血管変性、潰瘍形成）に対処するようにデザインされています。重症虚血肢（CLI）は慢性疾患であり、末梢動脈疾患（PAD）の最も深刻な形態です。

REX-001は、複数の免疫細胞と前駆細胞を下肢の疾患血管に直接送達する患者特異的細胞免疫療法として開発されています。現在、PADおよびその他の適応症を対象に、複数の施設で第III相臨床試験が行われています。

REX-001の局所投与により、有益な免疫調整細胞（成長因子やサイトカイン）が増強されます。この細胞は末梢血中にごく微量しか存在せず、疾患患者ではさらに減少します。

今後数年間で、末梢動脈疾患（PAD）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、REX-001の優位性に影響を与える可能性のある機会を模索しています。PADに対する他の新興製品がREX-001に厳しい市場競争を挑むと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における末梢動脈疾患（PAD）治療薬のREX-001市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 PADにおけるREX-001の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 REX-001市場評価

• PADにおけるREX-001の市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国のPADにおけるREX-001の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: REX-001, Clinical Trial Description, 2023
• Table 2: REX-001, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: REX-001 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: REX-001 Market Size in the US, in USD million (2019-2032)
• Table 7: REX-001 Market Size in Germany, in USD million (2019-2032)
• Table 8: REX-001 Market Size in France, in USD million (2019-2032)
• Table 9: REX-001 Market Size in Italy, in USD million (2019-2032)
• Table 10: REX-001 Market Size in Spain, in USD million (2019-2032)
• Table 11: REX-001 Market Size in the UK, in USD million (2019-2032)
• Table 12: REX-001 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: REX-001 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: REX-001 Market Size in the United States, USD million (2019-2032)
• Figure 3: REX-001 Market Size in Germany, USD million (2019-2032)
• Figure 4: REX-001 Market Size in France, USD million (2019-2032)
• Figure 5: REX-001 Market Size in Italy, USD million (2019-2032)
• Figure 6: REX-001 Market Size in Spain, USD million (2019-2032)
• Figure 7: REX-001 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: REX-001 Market Size in Japan, USD million (2019-2032)

"REX-001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about REX-001 for Peripheral Artery Disease (PAD) in the seven major markets. A detailed picture of the REX-001 for PAD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the REX-001 for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REX-001 market forecast analysis for PAD in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.

Drug Summary:

Multi-cell therapies (MCTs) derived from natural tissue extracts selected for the most active cells, removing components (such as red blood cells and platelets), potentially reducing the cells' therapeutic activity. Ixaka Ltd leads MCT product REX-001, a composite multi-cell product that builds on the established biology of using cells from a patient's bone marrow to treat CLTI. The product is an autologous bone-marrow-derived cell suspension enriched for white blood cells. It consists of a combination of progenitor cells and immune cells (lymphocytes, monocytes, granulocytes).

It is designed to address the complex disease processes (plaque deposition, inflammation, ischemia, vessel degeneration, ulcer formation) that lead to the clinical progression of CLTI. Critical limb ischemia (CLI) is a chronic condition and the most serious form of peripheral arterial disease (PAD).

REX-001 is being developed as patient-specific cellular immunotherapy that delivers multiple immune and progenitor cells directly to the diseased vessels of the lower leg. Currently, it is in a multi-site Phase III clinical trial to treat PAD and other indications.

Local administration of REX-001 boosts the beneficial immune-modulating cells (growth factors and cytokines), which are only present at very low levels in the peripheral blood and are further depleted in diseased patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the REX-001 description, mechanism of action, dosage and administration, research and development activities in Peripheral Artery Disease (PAD).
• Elaborated details on REX-001 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the REX-001 research and development activities in PAD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around REX-001.
• The report contains forecasted sales of REX-001 for PAD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PAD.
• The report also features the SWOT analysis with analyst views for REX-001 in PAD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REX-001 Analytical Perspective by DelveInsight

• In-depth REX-001 Market Assessment

This report provides a detailed market assessment of REX-001 for Peripheral Artery Disease (PAD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• REX-001 Clinical Assessment

The report provides the clinical trials information of REX-001 for PAD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Peripheral Artery Disease (PAD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REX-001 dominance.
• Other emerging products for PAD are expected to give tough market competition to REX-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REX-001 in PAD.
• Our in-depth analysis of the forecasted sales data of REX-001 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REX-001 in PAD.

Key Questions:

• What is the product type, route of administration and mechanism of action of REX-001?
• What is the clinical trial status of the study related to REX-001 in Peripheral Artery Disease (PAD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REX-001 development?
• What are the key designations that have been granted to REX-001 for PAD?
• What is the forecasted market scenario of REX-001 for PAD?
• What are the forecasted sales of REX-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to REX-001 for PAD?
• Which are the late-stage emerging therapies under development for the treatment of PAD?

Table of Contents

1. Report Introduction

2. REX-001 Overview in PAD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. REX-001 Market Assessment

• 5.1. Market Outlook of REX-001 in PAD
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of REX-001 in the 7MM for PAD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of REX-001 in the United States for PAD
  • 5.3.2. Market Size of REX-001 in Germany for PAD
  • 5.3.3. Market Size of REX-001 in France for PAD
  • 5.3.4. Market Size of REX-001 in Italy for PAD
  • 5.3.5. Market Size of REX-001 in Spain for PAD
  • 5.3.6. Market Size of REX-001 in the United Kingdom for PAD
  • 5.3.7. Market Size of REX-001 in Japan for PAD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options